Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature

Chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed (R/R) B-cell non-Hodgkin lymphoma (NHL). Several risk factors including CAR-T cell-related toxicities and their treatments often lead to infectious complicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercadal, Santiago, Gomez, Carlos A., Lee, Catherine J, Couriel, Daniel R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225770/
https://www.ncbi.nlm.nih.gov/pubmed/37246975
http://dx.doi.org/10.1007/s00277-023-05131-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225770/
https://www.ncbi.nlm.nih.gov/pubmed/37246975
http://dx.doi.org/10.1007/s00277-023-05131-7

Ejemplares similares